Pharmaceutical GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are prescription medications that have demonstrated significant effects in extensive clinical trials
It puts branded semaglutide products at roughly eight hundred to fourteen hundred dollars a month without insurance and branded tirzepatide higher still, against PlexusDx compounded semaglutide at $189/mo month-to-month, or from $149/mo on the 6-month plan
This provides a middle ground between purely systemic and directly local administration
atide etc.), By Duration (Long-acting GLP-1 Receptor Agonists, Short-acting GLP-1 Receptor Agonists), By Application (Type-2 Diabetes Mellitus, Obesity & Weight Management, Cardiovascular, Others), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and others Read more Healthcare Mar 2026 Pages 450 Report Format: PDF, Excel, PPT Global GLP-1 Receptor Agonist Market Projected 3.66% CAGR from 2026 to 2032 Study Period 2026-2032 Market Size (2026) USD 63.2 Billion Market Size (2032) USD 78.4 Billion Largest Region North America Projected CAGR 3.66% Leading Segments By Product Type: Semaglutide Global GLP-1 Receptor Agonist Market Report Key Takeaways: Market size was valued at around USD 52.39 billion in 2025 and is projected to grow from USD 63.2 billion in 2026 to USD 78.4 billion by 2032
Light, non-greasy formula absorbs easily without irritating sensitive skin
The old practice of pulling back on the plunger to check for blood is unnecessary for subcutaneous injection